Research Toward a Cure Trials
Ending HIV requires sustained research. TAG’s April 2026 cure trials update tracks clinical studies worldwide, helping advocates, researchers, and communities follow progress toward a cure.
TAG Statement on Results of the PreVenTB Phase III Trial of TB Vaccine Candidates VPM1002 and Immuvac
Well-conducted study sponsored by Indian Council of Medical Research did not meet primary efficacy endpoint of preventing microbiologically confirmed TB disease
The CDC’s Unjustified Halt on Testing for Dangerous Pathogens is Bad for Everyone’s Health – TAG Calls for CDC to Immediately Reinstate Essential Diagnostic Testing
CDC pauses rabies, mpox, and other infectious disease testing amid budget cuts and staffing losses, raising urgent public health concerns.
TAG Public Comments for the AIDS Research Advisory Council (ARAC) Meeting, April 6, 2026: Renewing Funding for the HIV Clinical Trial Networks
TAG recommends that the AIDS Research Advisory Council (ARAC) endorse NIAID's continued support of a balanced and comprehensive portfolio of basic, clinical, and implementation science — including a funding opportunity to renew its four current networks: the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the HIV Prevention Trials Network (HPTN), and the HIV Vaccine Trials Network (HVTN) or the updated IBPTN.
Near Point-of-Care TB Tests: What Communities Need to Know and Advocate for in Global Fund Grant Cycle 8
TB testing is getting faster, cheaper, and more accessible and advocates have a critical window to act. Treatment Action Group's new factsheet breaks down WHO-recommended near point-of-care TB tests and shows how communities can use Global Fund Grant Cycle 8 to finance their rollout. With an estimated 2.7 million people going undiagnosed in 2024 alone, the tools and funding are finally aligned. Now is the time to push for change.
World Tuberculosis Day 2026
On World TB Day, TAG is excited to share our most recent TB vaccine materials: a new TB vax-zine, community partnership report on emerging vaccines, supply chain analysis of adjuvants that boost vaccine effectiveness, and the most recent pipeline report on TB vaccines in development.
Treatment Action Group Welcomes Adam Ortega as Communications Director
TAG announced today the appointment of Adam Ortega as Communications Director. Adam brings experience in nonprofit marketing and public health and will lead TAG’s communications strategy to expand its reach and impact, and will deepen TAG as a leading voice in treatment advocacy, research, and community engagement on our work to end HIV, TB, and HCV as epidemics.
What TB Treatment Advocates Need to Know about aDSM/PV
Join TAG on April 16 at 8:30 a.m. ET for a practical webinar on drug safety monitoring in TB treatment. Learn how to identify side effects, support patient safety, and understand pharmacovigilance in the context of newer, all-oral DR-TB regimens.
TAG Condemns Latest U.S. “Forever” War in the Middle East, Calls for Reprogramming Billions from Military Aggression to Health and Research
TAG condemns the United States’ war in Iran and neighboring countries. At a time when U.S. investment in public health is being slashed, the Trump administration has chosen to spend billions of dollars per day on weapons used in a war of choice for which no credible rationale has been proposed. Our government should invest in our communities by spending funds that were already appropriated and illegally impounded by the White House Office of Management and Budget to keep people healthy, rather than starting new wars that put the entire world’s health at risk.
2026 CROI Tuberculosis Research Round Up
New tuberculosis research presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver offers important updates on TB prevention and treatment for people living with HIV. TAG summarizes key findings on short-course preventive therapy, treatment dosing strategies, and emerging long-acting technologies. Read TAG’s analysis.